Novartis AG (NVSEF)
OTCMKTS
· Delayed Price · Currency is USD
120.00
+4.87 (4.23%)
Jun 27, 2025, 9:41 AM EDT
Novartis AG Employees
Novartis AG had 75,883 employees as of December 31, 2024. The number of employees decreased by 174 or -0.23% compared to the previous year.
Employees
75,883
Change (1Y)
-174
Growth (1Y)
-0.23%
Revenue / Employee
$701,369
Profits / Employee
$169,458
Market Cap
235.02B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 75,883 | -174 | -0.23% |
Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Elite Pharmaceuticals | 64 |
Tian'an Technology Group | 8 |
American Oncology Network | 1,914 |
CytoDyn | 9 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
Silence Therapeutics | 116 |
Novartis AG News
- 21 hours ago - Final Trades: Novartis, Sixth Street, Amazon and the IYF - CNBC
- 23 hours ago - Novartis in deal with ProFound for cardiovascular disease therapies - Seeking Alpha
- 1 day ago - ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease - GlobeNewsWire
- 1 day ago - Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma - Benzinga
- 2 days ago - Novartis completes acquisition of Regulus Therapeutics - GlobeNewsWire
- 2 days ago - Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? - Investor's Business Daily
- 2 days ago - Novartis: A SWAN Worth Owning - Seeking Alpha
- 2 days ago - Novartis announces expiration of Regulus Therapeutics tender offer - GlobeNewsWire